-       Report 
- September 2024
-  184 Pages 
- Global 
   From       €2225EUR$2,500USD£1,958GBP 
          -       Report 
- May 2023
-  160 Pages 
- Global 
   From       €4404EUR$4,949USD£3,877GBP 
          -       Report 
- May 2024
-  160 Pages 
- Global 
   From       €4422EUR$4,969USD£3,892GBP 
          -       Drug Pipelines 
- January 2019
-  163 Pages 
- Global 
   From       €19577EUR$22,000USD£17,233GBP 
          -       Report 
- July 2018
-  14 Pages 
- Global 
   From       €8899EUR$10,000USD£7,833GBP 
                    Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the    naturally occurring enzyme plasminogen.
The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less   Read more